Interview with Jean-Luc Bélingard, CEO, Ipsen France
As the G5 brings together five very different companies – Ipsen, LFB, Pierre Fabre, Sanofi-Aventis, Servier – could you explain the origin behind the creation and the purpose of the…
Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer or neuroendocrine tumors. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen’s R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis, France; Slough/Oxford, UK; Cambridge, US).
2015 has been Ipsen´s best year since becoming a publicly traded company, marked by their take-off in the US. In 2016 the US will overtake France to become their number one affiliate. Besides an excellent 2015 operating performance, sales grew by more than 10% year-on-year, driven by the successful launch of Somatuline in neuroendocrine tumors in the US and Europe, and the performance of Dysport in aesthetics. Core operating income grew by close to 24%, reflecting continuous transformation and cost monitoring efforts.
Contact
Address: 65 Quai Georges Gorse 92100, Boulogne-Billancourt,France
Tel: +33 (0)1 58 33 50 00
Web: http://www.ipsen.com/en/ipsen-worldwide
As the G5 brings together five very different companies – Ipsen, LFB, Pierre Fabre, Sanofi-Aventis, Servier – could you explain the origin behind the creation and the purpose of the…
Most players entered the generic pharmaceutical industry in France in the late 1990s into the 2000s yet Actavis decided to enter much later – in late 2007 – through an…
CIP and GERS have very unique relationships with the pharmaceutical industry. Could you elaborate on the role of these two bodies? Club Inter-pharmaceutique (CIP) is a professional association created in…
As a majority of our readers are American that may be used to a different model of clusters can you explain the unique characteristics of the pôles de compétitivité? The…
Aricept has been a very effective blockbuster for the group as a whole and the loss of exclusivity affects not only France but entire company. How is Eisai in France…
There is a lot of change occurring in the French pharmaceutical industry at the moment and this is no different for Boehringer Ingelheim. Just last September you moved into these…
As president of LEEM, what will be your legacy and what legacy would you like to instill in the organization? A legacy of re-industrialization in the French pharmaceutical and health…
Roche has a long history in France and currently enjoys a higher position than its worldwide ranking. Can you elaborate on the importance of this market for the group overall?…
Do you feel the industry has changed more over the past ten years than over the entire 40 years before? It’s an optical illusion. People always have had the feelings…
As the G5 brings together five very different companies – Ipsen, LFB, Pierre Fabre, Sanofi-Aventis, Servier – could you explain the origin behind the creation and the purpose of the…
You’ve been at the head of AstraZeneca France for 7 years through during which time there has been a lot of M&A activity in the industry as well as a…
FEFIS represents 11 different associations across the industry with a very broad scope. How does the organization represent all of these different sectors? FEFIS represents as much as possible activities…
After spending 15 years at the CEA (Nuclear Energy Center), you just accepted an offer to become the General Manager of INSERM at the very moment a political reform is…
See our Cookie Privacy Policy Here
